Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

BACKGROUND: Patients with type 2 diabetes and chronic kidney disease are at high risk for kidney failure, cardiovascular events, and death. CONCLUSIONS: Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 Whether treatment with semaglutide would mitigate these risks is unknown.
• 2 METHODS: ), at least a 50% reduction in the eGFR from baseline, or death from kidney-related or cardiovascular causes.
• 3 Prespecified confirmatory secondary outcomes were tested hierarchically.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: